MATERIALS AND METHODS

Synthetic peptides
Two decapeptides and one nonapeptide of RBP-1 were synthesized with a free COOH and NH 2 terminal at Research Genetics, Inc. (Huntsville, AL, USA). KASIFLKTRV and KASIFLKTR were easily dissolved in standard culture medium; GLQKASIFLK was insoluble in standard medium and therefore was dissolved in 100% dimethyl sulphoxide (DMSO) at 100 mg ml -1 and stored at -20°C. Prior to use, all three peptides were diluted to 100 µg ml -1 in a culture medium and stored at 4°C for no more than 2 weeks.
Cell line establishment
Eleven breast cancer primary cultures were established from metastases of individual patients as follows: surgical specimens were minced and treated with RPMI-1640 containing 0.02% trypsin, 200 U ml -1 of DNAase I and 0.15 g ml -1 of collagenase (Sigma, St Louis, MO, USA) for 2 h at 37°C to make a single-cell suspension. Cells were seeded to 12-well culture plates and cultured in RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS) (Gemini Bioproducts, Calabasas, CA, USA) plus penicillin G, streptomycin and amphotericin B (Gibco-BRL, Grand Island, NY, USA). Non-adherent cells were removed 2 days later. A homogeneous cancer cell population was selectively developed by cloning and passaging. These cells were maintained in the above medium supplemented with insulin and transferrin. JWCI-BA, a long-term (> 30 passages) breast cancer cell line that expressed the breast cancer-associated KASIFLK antigen was HLA-A2, A3, which was maintained in the same culture medium was used in certain experiments. Fibroblastoid and epidermoid primary cultures representative of normal cell controls were established as previously described. Epidermal cells were obtained by scraping a thin layer of epidermis, which was separated from dermis by culturing overnight with RPMI-1640 containing 0.3% trypsin. JWCI-MA, which is a KASIFLK-negative, HLA-A2, A3 melanoma cell line (> 20 passages), was also used as a control. All cell lines were subjected to immunohistochemical analysis using a human anti-KASIFLK IgG antibody. All control cell lines were proven to be negative for the KASIFLK antigen, and all breast cancer cell lines were positive for the antigen. Viral-transformed BLC lines were established from normal donors by incubating PBMC with Epstein-Barr virus (EBV) obtained from supernatant of B95-8 marmoset BLC line (Morioka et al, 1994) . HLA typing of all cell lines was carried out by HLA antibody microcytotoxicity assay (Dr Paul Terasaki's laboratory at the UCLA School of Medicine) and/or by DNA polymerase chain reaction (PCR) assay. These assays tested peripheral blood lymphocytes from donors of the cell lines.
Generation of CTL lines
PBMC were obtained from fresh blood of 41 normal healthy donors by fractionation with Ficoll Hypaque gradient (Pharmacia Biotech, Alameda, CA, USA). PBMC (3 × 10 6 per well) were cultured in a 24-well culture plate with AIM-V media (Gibco-BRL) containing 10% human AB heat-inactivated serum (Gemini Bioproducts) and 10 µg ml -1 of synthetic peptide. After 2 days, half of the culture medium was replaced with fresh medium supplemented with 15 IU ml -1 (final concentration) of interleukin-2 (IL-2) (R&D Systems, Minneapolis, MN, USA) and 25 IU ml -1 of interleukin-7 (IL-7) (R&D Systems). PBMC were transferred to new wells to remove adherent cells. This procedure was repeated every 2 days to completely remove adherent cells before the next peptide stimulation. After 6 days, 3 × 10 6 of cryopreserved autologous PBMC were thawed and incubated for 6 h with culture medium containing 500 IU ml -1 of granulocyte-macrophage colony-stimulating factor (GM-CSF) (R&D Systems) and 10 µg ml -1 of the peptide. PBMC were then irradiated at 5000 rads and non-adherent cells were removed and used as feeder cells. Responder cells were added to these adherent cells and then cultured. Two days later, half of the medium was replaced with fresh medium containing IL-2 and IL-7, and the responder cells were transferred to new wells. The same procedure was repeated. At day 30, all responder cells were tested for cytotoxicity against autologous EBV-transformed BLC pulsed with peptide. Successful peptide-specific CTL lines were maintained for more than 16 weeks by restimulation with peptide and cytokines every 6th day.
51
Cr-release cytotoxic assay 51 Cr-release cytotoxic assay was performed as previously described (Morioka et al, 1994) . Target cells were labelled with 100 µCi of Na 2 51 CrO 4 (Amersham, Arlington Heights, IL, USA). BLC targets were prepulsed with 10 µg ml -1 of the peptide for 2 h at 37°C before effector cells were added. The percentage of specific lysis was calculated as follows: 100 × [(experimental releaseϪspontaneous release)/(maximum releaseϪspontaneous release)]. Spontaneous release was determined by incubating target cells with medium only, and maximum release was determined with 3% Triton X-100. Spontaneous release and maximum release were counted in BLC targets with and without peptide; no differences were observed. All values were the average from triplicate samples.
Monoclonal antibody blocking
An antibody blocking assay was performed to assess CTL specificity. 51 Cr-labelled target cells were incubated at 37°C with IgG murine monoclonal antibody (mAb) against HLA class 1, HLA-DR, and HLA-DQ (AMAC, Inc., Westbrook, ME, USA); HLA-A2 (clone BB7.2 ATCC); or HLA-A3 (clone GAP A3 ATCC). After 30 min, effector cells were added, and 51 Cr-release CTL assay was performed as described above.
Cold target inhibition assays
Effector cells were incubated with unlabelled cold targets (fibroblasts, PBMC, K562 cells and JWCI-BA breast cancer cell line) at specific ratios in 96-well round-bottom microtitre plates for 1 h at 37°C. 51 Cr-labelled hot targets were then added to the wells and incubated at 37°C for 4 h. The E:T ratio was constant at 40:1.
RESULTS
HLA-A2 or HLA-A3 restricted recognition of RBP-1 peptide by CTL
The peptide sequences selected in this study -GLQKASIFLK, KASIFLKTRV, and KASIFLKTR -were derived from the natural RBP-1 protein sequences 247-256, 250-259 and 250-258, respectively, and contain HLA-A2 and/or HLA-A3 motifs adjacent to the N-and/or C-terminal of the antibody-recognizing heptameric sequence KASIFLK. GLQKASIFLK has anchor motifs for both HLA-A2 and HLA-A3. K at position 10, L at position 9 and L at position 2 are preferred anchor residues of HLA-A2. L at position 2 and K at position 10 are preferred anchor residues of HLA-A3. KASIFLKTRV also has anchor motifs for HLA-A2 and HLA-A3: A at position 2 and V at position 10 for HLA-A2, and A at position 2 and R at position 9 for HLA-A3. KASIFLKTR has a motif for HLA-A3 only: A at position 2 and R at position 9. PBMC from 41 normal healthy donors were stimulated with these peptides: 15 expressed HLA-A2, 10 expressed HLA-A3, four expressed HLA-A2 and HLA-A3 and 12 did not express HLA-A2 or HLA-A3 but did express other HLA-A motifs. These binding motifs were based on several published references (Celis et al, 1994a; Kawakami et al, 1994; Rammensee et al, 1995; Rivoltini et al, 1995; Sidney et al, 1996) .
The cytotoxicity of each peptide-specific cell line was assessed using autologous BLC pulsed with the respective peptide. Stimulation by GLQKASIFLK, which has motifs for both HLA-A2 and HLA-A3, generated strong CTL from HLA-A2 donors and relatively weaker CTL from HLA-A3 donors. Cytotoxicity was greater than 20% for CTL generated from four of four HLA-A2, A3 donors, 11 of 15 HLA-A2 donors, and five of ten HLA-A3 donors. None of the CTL generated from 16 donors with other HLA types (HLA-A2 -, A3 -) showed specific cytotoxicity greater than 10%. These findings suggest that the recognition of GLQKASIFLK by CTL is restricted by both HLA-A2 and HLA-A3. 3.3 ± 0.3 1.4 ± 0.1 0.9 ± 0.1 3.5 ± 0.3 3.8 ± 0.3 2 1, 2 42.7 ± 1.8 2.9 ± 0.3 26.6 ± 1.4 4.1 ± 0.4 0.0 ± 0.1 0.0 ± 0.2 3 1, 3 30.8 ± 1.4 3.1 ± 0.3 6.7 ± 0.5 7.2 ± 0.4 2.2 ± 0.2 2.1 ± 0.1 4 1, 24 5.4 ± 0.2 6.0 ± 0.4 3.5 ± 0.3 3.2 ± 0.3 4.4 ± 0.4 4.6 ± 0.3 5 2, 2 48.5 ± 1.9 5.1 ± 0.3 29.4 ± 0.9 8.9 ± 0.6 0.6 ± 0.2 1.5 ± 0.1 6 2, 3 58.9 ± 1.8 3.8 ± 0.3 35.1 ± 1.4 3.8 ± 0.2 5.3 ± 0.5 4.6 ± 0.3 7 2, 32 53.6 ± 21.5 7.2 ± 0.5 17.6 ± 0.9 2.4 ± 0.2 3.9 ± 0.3 3.3 ± 0.3 8 3, 11 29.3 ± 1.0 1.8 ± 0.2 13.7 ± 0.9 2.5 ± 0.2 11.8 ± 0.7 2.4 ± 0.3 9 3, 31 37.4 ± 1.0 6.5 ± 0.5 3.2 ± 0.3 3.6 ± 0.3
a PBMC from normal donors were stimulated for 4 weeks with each of the three RBP-1 peptides and tested for their cytotoxicity using 51
Cr-release assay. b Target cells were autologous EBV-transformed BCL with and without each peptide. c Data are expressed as average per cent specific cytotoxicity and standard deviation of two independent cytotoxicity assays at an E:T ratio of 40:1. Bold-face type indicates significant cytotoxicity of targets when peptide-pulsed. KASIFLK overexpression, as determined by immunohistochemical analysis using a human antibody to KASIFLK. c All CTL lines were tested for specific cytotoxicity after 4 weeks of stimulation with specific peptide. d Donor nos 5-8 are identical to the donors in Table 1 . e Data are expressed as average per cent cytotoxicity and standard deviation of two independent cytotoxicity assays at an E:T ratio of 40:1.
CTL cultures that showed significant cytotoxicity were further stimulated with peptides and established into CTL lines. RBP-1 peptide KASIFLKTRV, which has a motif for both HLA-A2 and HLA-A3, was less effective than GLQKASIFLK in CTL generation. Cytotoxicity against peptide-pulsed BLC was greater than 20% for CTL generated from ten of 15 HLA-A2 donors but zero of ten HLA-A3 donors (data not shown). This suggests that KASI-FLKTRV is presented primarily in the context of HLA-A2. The nonamer KASIFLKTR has a motif for HLA-A3 but showed only weak activity for eliciting peptide-specific CTL; only one CTL line (from an HLA-A3 donor) demonstrated cytotoxicity greater than 10%. Twelve representative CTL lines against the three peptides were consecutively generated from 12 different patients (Table 1) .
The HLA restriction of CTL was then assessed using one established breast cancer cell line and ten breast cancer primary cell lines as targets. Five GLQKASIFLK-specific and four KASI-FLKTRV-specific CTL lines, all derived from HLA-A2 or HLA-A3 PBMC, were tested for their cytotoxicity against seven HLA-A2 and/or HLA-A3 breast cancer cell lines, four HLA-A2 -,
A3
-breast cancer cell lines, K562 cell line (susceptible to LAK cells) and 8392 cell line (not susceptible to LAK cells). As shown in Table 2 , the results further supported HLA-A2 and HLA-A3 restricted recognition of GLQKASIFLK and KASIFLKTRV, although HLA-A3 restricted recognition of the latter peptide was at a very low level. No significant lysis of breast cancer cell lines occurred when PBMC were cultured for 4 weeks without peptide or from HLA-A2 -, A3 -PBMC stimulated with peptide (data not shown). The specific lysis of HLA-A2, A3 breast cancer cells by peptide-specific CTL was inhibited by mAb against HLA-A2, HLA-A3 or anti-HLA class I, but not by mAb against HLA-DQ or HLA-DR (Figure 1) . . Cytotoxicity is shown as percent specific cytotoxicity. Background cytolysis of breast cancer cells expressing other HLA types and nonpulsed BLC was < 2.5% Figure 2 shows the maturation pattern of representative CTL lines established by stimulation with each of the three RBP-1 peptides. Although a higher cytotoxicity was observed in cell lines stimulated with GLQKASIFLK than in cell lines stimulated with KASI-FLKTRV, the pattern of stimulation was similar. After 4 weeks, cytotoxicity against breast cancer cells and peptide-pulsed BLC reached a plateau. The number of cells and specificity of the cell lines at week 4 decreased when peptide stimulation was interrupted, whereas CTL lines at week 16 were quite stable for both cell growth and specificity. The phenotyping of CTL lines against GLQKASIFLK or KASIFLKTRV at wk 16 revealed that these cells were predominantly CD3 + , CD8 + , CD4 -. CTL lines stimulated for 16 wk with GLQKASIFLK and KASI-FLKTRV were tested against autologous BLC pulsed with 0.01-100 µM of the corresponding peptide at an E:T ratio of 40:1 (Figure 3) . Cytotoxicity increased in a dose-dependent manner until peptide concentration reached 1 µM.
Kinetics of CTL maturation
Assessment of cross-reactivity among three peptidespecific CTL
PBMC from an HLA-A2, A3 donor were stimulated for 16 weeks with each of the three RBP-1 peptides. The cytotoxic activity of the three ensuing CTL lines was assessed using an autologous BLC cell line pulsed with each peptide. As shown in Figure 4 , GLQKASIFLK-specific and KASIFLKTRV-specific CTL lines had 51.2% and 38.1% specific cytotoxicity, respectively, against BLC pulsed with the respective stimulating peptide, but did not show significant cytotoxicity against BLC pulsed with the non-stimulating peptides. KASIFLKTR-specific CTL showed minimum cytotoxicity against KASIFLKTR-pulsed BLC (13.7%) and against the HLA-A2, A3 breast cancer cells (15.4%). PBMC from donor number 19 (HLA-A2, A3) were repetitively stimulated with GLQKASIFLK or KASIFLKTRV, and their toxicity against GLQKASIFLKpulsed (v) and KASIFLKTRV-pulsed (v v) autologous BLC and against HLA-A2, A3 breast cancer cell line JWCI-BA (q,) was assessed at an E:T ratio of 40:1. Cytotoxicity against non-pulsed BLC was < 4.0% and subtracted from each peptide-pulsed BLC cytotoxicity Peptide-specific CTL activity against normal cells and melanoma cells
Autologous or allogeneic HLA-A2 or HLA-A3 matched normal cells (fibroblasts, epidermal cells and PBMC) and a melanoma cell line (HLA-A2, A3) were not recognized by GLQKASIFLKspecific or KASIFLKTRV-specific CTL (Table 3) . Furthermore, while the cytotoxicity of both CTL lines was almost completely inhibited by cold target breast cancer cells at a cold:hot target cell ratio of 20:1, cytotoxicity was not affected by K562 cells, autologous normal fibroblasts or HLA-A2, A3 melanoma cells used as cold targets, even at the ratio of 80:1 ( Figure 5 ).
DISCUSSION
In this study we analysed CTL activity against specific peptide sequences of RBP-1. Previously, we demonstrated that an RBP-1 peptide sequence, KASIFLK, is recognized by human antibodies. KASIFLK peptide was detected by antibody staining in 12 of 15 (80%) breast cancer specimens, but not in 50 normal tissues (Cao et al, 1999) . In the present study we demonstrate that the heptameric peptide KASIFLK is recognized by CTL. The inclusion of adjacent amino acids on the NH 2 or COOH terminal of KASIFLK provided the necessary length and HLA-A anchor motifs for HLA-restricted T-cell recognition. RBP-1 peptides GLQKASIFLK and KASI-FLKTRV, both of which contain KASIFLK, stimulated peptidespecific CTL that recognized respective BLC peptide-pulsed target cells and breast cancer cell lines. Presence of the peptide binding motifs does not always predict HLA-restricted CTL recognition. The peptide KASIFLKTR that contains HLA-A3 motifs, A at position 2 and R at position 9, did not induce an effective CTL response (Table 1 ). This may be explained by weak antigenicity and/or weak binding of the peptide to the HLA molecule. An effective peptide sequence for CTL induction depends on multiple factors. In our system, we can narrow the selection criteria by using a CTL peptide sequence built around an antigenic epitope recognized by a human antibody. The dual effector arms recognizing tumour-associated antigen peptides do not appear rare (Morioka et al, 1994; Takahashi et al, 1997a Takahashi et al, , 1997b , and such peptides may represent potential antigens for active specific immunotherapy.
Immunohistochemical analysis has shown that the specific antibody recognizing the RBP-1 heptamer peptide sequence KASIFLK binds predominantly to breast cancer tissues and breast cancer cell lines (Cao et al, 1999) . Although normal cells as well as other types of cancer cells express RBP-1 mRNA, the antibody failed to detect the epitope in these cells. We initially attributed this to the level of expression of the specific peptide sequence and/or to conformational or post-translational changes of the protein in breast cancer cells. Future studies will determine the RBP-1 protein expression levels and the post-translational modifications in normal and breast cancer cells. However, we have not excluded the possibility that other proteins expressing KASIFLK or cross-reactive peptides are responsible for the antibody staining of the proteins and/or CTL recognition of the peptides.
The overexpression of the RBP-1 peptide or cross-reactive peptides in breast cancer cells may play a major role in the CTL . Specific cytotoxicity is the mean of three independent assays performed at an E:T ratio of 40:1.
Figure 5
Cold target inhibition of GLQKASIFLK-specific HLA-A2, A3 CTL against allogeneic HLA-A2, A3 breast cancer cell line JWCI-BA (A) and autologous GLQKASIFLK-pulsed BLC (B). The CTL line was derived from donor number 19 (HLA-A2, A3). Autologous PBMC (q q), HLA-A2, A3 melanoma cells (v v), autologous fibroblasts from normal dermal tissues (s s), K562 cells (v), and JWCI-BA breast cancer cell line (q) were used as cold targets. Cytotoxicity assays were performed at an E:T ratio of 40:1. Nonlabelled cold targets were added at the indicated ratios to the hot targets antigenicity of breast cancer cells. The human antibody detects the core peptide antigen, KASIFLK, predominantly in the cytoplasm of breast cancer cells. Antigen presentation with HLA class I molecules requires cytosolic processing and transportation (Germain, 1994; Heemels and Pleogh, 1995) . Therefore, CTL recognition of the peptides in breast cancer cells may be related to intracellular antigen processing that influences HLA presentation on the cell surface (Nijman et al, 1994) .
We observed that RBP-1 peptide-specific CTL could be generated relatively easily by in vitro stimulation from HLA-A2 and HLA-A3 healthy donor PBL. This suggests that the peptide is quite antigenic. However, CTL killing was observed only against individual breast cancer cells, not against normal cells. A similar observation has been made for the tumour-associated antigens MAGE-1 and MAGE-3. MAGE-1 and MAGE-3 specific CTL can be generated from normal healthy donors as well as from the PBL of cancer patients; these CTL recognize tumour cells expressing moderate levels of the respective MAGE antigen (Traversari et al, 1992; Boon et al, 1994; Celis et al, 1994b) . These observations indicate that the antigenic peptide sequence might be recognized only on tumour cells that overexpress the peptide.
RBP-1 can promote tumour growth by inhibiting the function of pRB. RBP-1 binds pRB at the binding motif (LXCXE) (Fattaey et al, 1993) . Overexpression of RBP-1, as occurs in breast cancer, may promote active proliferation of tumour cells. CTL recognition of tumour cells expressing the RBP-1 peptide antigen would be important in developing active specific immunotherapies for prophylactic and therapeutic control of breast cancer. HLA-A2 and HLA-A3 molecules are found in high frequency in the general population and therefore offer a considerable advantage over a single HLA-A or HLA-B restricted peptide sequence (Hoon et al, 1998) . Recently, several other tumour-associated proteins that are related to cell growth and cell cycle regulation, such as p53, HER2/NEU2 and p21 (RAS), have been shown to be antigenic (Nijman et al, 1994; Peace et al, 1994; Peoples et al, 1994; Gnjatic et al, 1995; Van Elsas et al, 1995) . In future studies we will assess the in vivo immunogenicity of RBP-1 peptides by studying PBMC from breast cancer patients.
